# NGM Biopharmaceuticals: Research, South San Francisco, United States

> NGM Biopharmaceuticals: NGM Biopharmaceuticals Inc. Based in South San Francisco, United States. Founded 2008.

Source: https://millionrounds.com/startup/ngm-biopharmaceuticals (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# NGM Biopharmaceuticals

NGM Biopharmaceuticals Inc.

Funding reported Last round: Series A

Research South San Francisco, United States

Company summary

- **Founded:** 2008 18 years old
- **Team:** 73 51 to 200 people
- **Funding reported:** $542M in dollars
- **Last round:** Series A Jul 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for NGM Biopharmaceuticals has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About NGM Biopharmaceuticals

NGM Biopharmaceuticals Inc.

(NGM Bio) is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2007, the company focuses on discovering and developing innovative medicines for serious health conditions. NGM Bio is currently concentrating on its lead product, NGM120, a GDF15/GFRAL antagonist antibody, which is in Phase 2 clinical trials for hyperemesis gravidarum and cancer cachexia. The company has a diverse pipeline that includes therapeutics targeting various diseases such as cardio-metabolic, liver, oncologic, and retinal conditions. NGM Bio employs a biology-centric drug discovery approach, integrating complex disease biology with protein engineering to advance its biologic candidates. Collaborating with Merck Sharp & Dohme Corp. and Merck & Co., Inc., NGM Bio aims to develop novel treatments for unmet medical needs, particularly in the areas of severe pregnancy-related nausea and cancer-related weight loss.

## What company datasets say NGM Biopharmaceuticals raised

Funding, as reported

Reported in all **$542M** in dollars

Rounds **7**

Last round **Series A**

Last round size **$122M**

Last round date **Jul 2024**

Investors listed **9**

SEC Form D **$341M sold, 10 filings, last Mar 2015**

## Founders and team

From NGM Biopharmaceuticals's own website and the SEC filings it signed: 5 on the team.

- **Diana Peng Bockus** Chief Executive Officer
- **Tianny Szeto** Vice President, Finance
- **William Chang** Vice President, Clinical Operations
- **Jin-Long Chen** Executive Officer, Director i
- **William J. Rieflin** Executive Officer, Director i

On the board, as filed i *David V. Goeddel* *David V. Schnell* *Mark V. Leschly* *McHenry T. Tichenor* *Peter V. Svennilson*

## On 2 portfolio pages

Investors who name them

- [The Column Group](https://millionrounds.com/fund/the-column-group)
- [Prospect Venture Partners](https://millionrounds.com/fund/prospect-venture-partners)

Each firm lists NGM Biopharmaceuticals on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

marketing strategy biologic drug candidates health care user experience liver disease treatments biotech therapeutics biotechnology research biological pathway healthcare providers healthcare solutions collaboration partnership opportunities in-house innovation medical research oncology drugs healthcare data

Built with from their website

Adobe Google Tag Manager UserWay WordPress.org Google Workspace Gem Viewport Meta webpack C3.js Sophos Email

+8 more

Google Meet Priority Hints React Sophos Central Mobile Friendly Greenhouse Vercel Open Graph

- **Sector:** Research
- **Industry code:** NAICS 541714, 325414, SIC 2834
- **Region:** California
- **Revenue:** $3.6M a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/ngm-biopharmaceuticals)

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put NGM Biopharmaceuticals in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)